On Wednesday, CME Group Inc(NASDAQ:CME)’s shares declined -0.24% to $97.02.
CME Group, the world’s leading and most diverse derivatives marketplace, recently declared that July 2015 volume averaged 12.8 million contracts per day, up 5 percent from July 2014. Total volume was more than 282 million contracts, of which 87 percent was traded electronically. Options volume in July averaged 2.9 million contracts per day, up 22 percent as compared to July 2014, with electronic options growing 36 percent over the same period.
CME Group interest rate volume averaged 5.9 million contracts per day in July 2015, down 5 percent contrast with July 2014. Treasury average daily volume rose 3 percent, with treasury futures volume of 2.2 million contracts per day, down 2 percent from the same period a year ago. Treasury options volume grew 27 percent to more than 634,000 contracts per day and comprised of record weekly treasury options average daily volume of 147,707. Eurodollar futures volume averaged 2.1 million contracts per day, down 20 percent contrast with July 2014. Eurodollar options volume averaged 927,000 contracts per day, up 14 percent, driven by 62 percent growth in Eurodollar options traded on the CME Globex platform. In July, 21 percent of the Eurodollar options volume traded electronically.
CME Group Inc., through its auxiliaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers a range of products for trading and/or clearing across various asset classes, based on interest rates, equity indexes, foreign exchange, energy, agricultural commodities, and metals.
Celladon Corp (NASDAQ:CLDN)’s shares dropped -4.46% to $1.07.
Celladon Corporation (CLDN), declared financial results for the quarter ended June 30, 2015 and recent corporate updates.
Second Quarter 2015 and Recent Corporate Updates
- In April, Celladon declared that its Phase 2b CUPID2 trial did not meet its primary or secondary endpoints. CUPID2 is a randomized, double-blind, placebo-controlled, multinational trial evaluating a single, one-time, intracoronary infusion of the cardiovascular gene therapy agent MYDICAR(R) (AAV1/SERCA2a) as compared to placebo added to a maximal, optimized heart failure drug and device regimen.
- In June, Celladon confirmed its plans to suspend further research or development of its MYDICAR (AAV1/SERCA2a) program and its other programs counting the Stem Cell Factor (mSCF) gene therapy and SERCA2b small molecule programs.
- In the second quarter of 2015, Celladon’s Board of Directors approved an about 70% reduction of Celladon’s workforce in order to reduce operating expenses and conserve cash resources as the Company evaluates planned alternatives in light of the negative CUPID2 data.
Celladon Corporation, a clinical-stage biotechnology company, focuses on developing cardiovascular gene therapy and calcium dysregulation. The company’s lead product candidate comprises MYDICAR that uses genetic enzyme replacement therapy to correct the Sarco/endoplasmic reticulum Ca 2+ -ATPase 2a enzyme deficiency in heart failure patients that result in inadequate pumping of the heart. Its MYDICAR product is used to treat patients with systolic heart failure, diastolic heart failure, and advanced heart failure, in addition to treat pulmonary arterial hypertension and arteriovenous fistula maturation failure.
At the end of Wednesday’s trade, CTI BioPharma Corp (NASDAQ:CTIC)‘s shares showed no change to $1.79.
CTI BioPharma Corp. (CTIC) declared findings from an investigator-sponsored Phase 2 trial in patients with either primary (de novo) acute myeloid leukemia (AML) or AML that has evolved from myelodysplastic syndrome (MDS). Results showed the combination of tosedostat with low dose cytarabine/Ara-C (LDAC) resulted in an overall response rate (ORR) of 54 percent in elderly patients with AML – with 45 percent of patients achieving durable complete responses (CR). These final results were presented by Dr. Giuseppe Visani, Director of Hematology and Stem Cell Transplant Center at AORMN, Pesaro, Italy in a poster session (abstract #P564) during the 20th Congress of the European Hematology Association (EHA), June 11-14, 2015 in Vienna, Austria.
AML is the most common acute leukemia affecting adults, and its incidence enhances with age. AML may develop from the progression of other diseases, such as MDS, which is a blood cancer that also affects the bone marrow and leads to a decrease in circulating red blood cells. Tosedostat is a potential first-in-class selective inhibitor of aminopeptidases, which are required by tumor cells to provide amino acids necessary for growth and tumor cell survival.
CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It primarily focuses on the commercialization of PIXUVRI, an aza-anthracenedione derivative for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma in the European Union. The company is also developing Pacritinib, an oral multikinase inhibitor with activity against Janus Kinase 2 and FMS-like tyrosine kinase, which is in Phase III clinical trials for the treatment of myelofibrosis. In addition, it is developing Tosedostat, an oral once-daily aminopeptidase inhibitor that is in Phase II/III clinical trials for the treatment of acute myeloid leukemia; and Opaxio, a chemotherapeutic agent, which is in Phase III clinical trials for the treatment of various solid tumors, counting non-small cell lung, ovarian, breast, and prostate cancers.
Pioneer Energy Services Corp (NYSE:PES), ended its Wednesday’s trading session with -0.81% loss, and closed at $3.69.
Pioneer Energy Services (PES) stated financial and operating results for the quarter ended June 30, 2015. Notable items for the second quarter and recent developments comprise:
- Well servicing rig utilization was 73% with average pricing of $595 per hour.
- Drilling utilization in the second quarter was 63% based on an average fleet of 37 rigs.
- Year-to-date sold 27 mechanical and lower horsepower electric drilling rigs for net proceeds of $33.4 million and have one additional rig designated as held-for-sale.
- Mobilizing the second of five new-build 1,500 horsepower AC drilling rigs planned to be delivered in 2015.
- Presently have 17 rigs earning under contract, which comprises six rigs earning but not working.
Pioneer Energy Services Corp., through its auxiliaries, provides drilling services and production services to oil and gas exploration and production companies in the United States and Colombia.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
